Advertisement

Decision Aids Reduce Men's Conflict about PSA Screening, but Don't Change Their Decisions

Advertisement

Key Points

  • Researchers found that both Web-based and print tools increased men's knowledge about PSA screening, reduced the initial conflict they reported about their decision, and increased their immediate satisfaction with their decision.
  • The decision aids did not have an impact on the men’s screening decisions when measured a year later, but instead increased their long-term satisfaction with their decisions.

Men who decide to be screened for prostate cancer and those who forgo PSA screening stick with their decisions after receiving materials explaining the risks and benefits of the test, according to a study published in JAMA Internal Medicine. The study examined both Web-based and printed tools aimed at helping men make informed decisions about PSA testing. The decision aids greatly increased their knowledge about screening and reduced their conflict about what to do, but did not have an impact on their screening decision when measured a year later.

In May 2012, the U.S. Preventive Services Task Force recommended against screening all men for prostate cancer. Most health professional groups recommend shared decision-making so that men can understand the limitations of screening before making a decision about being tested.

"The history of conflicting recommendations for prostate cancer screening and the mixed messages about screening effectiveness make it critical to assist men in making informed decisions," explained lead author Kathryn Taylor, PhD, Professor in the Cancer Prevention and Control Program at Georgetown Lombardi Comprehensive Cancer Center.

Study Details

Dr. Taylor and her colleagues developed two decision aids to help men weigh the pros and cons of testing and then make informed decisions about screening. In one of the largest and most representative randomized trials conducted on this topic, a racially diverse group of 1,879 men aged 45 to 70 were randomly assigned to utilize a print-based decision aid (n = 628), an interactive Web-based decision aid (n = 625), or usual care (n = 626). Telephone interviews were conducted at the start of the study, 1 month after the start, and again at 13 months to see if the tool had a long-term impact.

"The tools were intended neither to encourage nor discourage screening, but instead to present the benefits and limitations of screening to help men make choices consistent with their preferences," Dr. Taylor explained.

After the surveys were conducted, the researchers found that both the Web-based and print tools increased the men's knowledge and reduced the initial conflict they reported about whether or not to be screened (all P < .001), and increased their immediate satisfaction with their decision.

Positive Trend in Long-term Satisfaction

"Interestingly, we thought these decision aids might lead to more men forgoing testing, but in fact, the men didn't change their screening plans," said Dr. Taylor, adding, "The men told us these tools helped them resolve their own conflicts about whether or not to receive screening." The study suggested a positive trend in men's long-term satisfaction with their decisions, which is important because men face the decision about screening every year.

"Ultimately, the decision to receive PSA screening for prostate cancer lies with men," Dr. Taylor concluded. "They'll be able to make decisions that are right for them if they have unbiased, updated screening materials that fully explain the risks and benefits," she said.

Importantly, the print- and Web-based decision aids were equally effective in improving knowledge and reducing decisional conflict, suggesting that either tool may be used, depending on an individual's preferred medium, Dr. Taylor said.

"They both have the potential to be easily adopted in real-world practice settings," Dr. Taylor concluded. "Given the demonstrated beneficial effect of the decision aids, work is now needed to understand the best methods for widespread dissemination."

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement




Advertisement